Pediatric multiple sclerosis

CONTINUUM Lifelong Learning in Neurology

Volumn 16, Issue 5, 2010, Pages 181-192

  Mowry, Ellen M ^a   Waubant, Emmanuelle ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA1A INTERFERON; CIGARETTE SMOKE; GLATIRAMER; HLA DR ANTIGEN; IBUPROFEN; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ADRENOLEUKODYSTROPHY; ARTICLE; ATAXIC APHASIA; BEHCET DISEASE; BRAIN DISEASE; BRAIN LYMPHOMA; CADASIL; CANAVAN DISEASE; CEREBROSPINAL FLUID; CHILDHOOD DISEASE; CLINICAL FEATURE; CYANOCOBALAMIN DEFICIENCY; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMETRIA; EPSTEIN BARR VIRUS INFECTION; GENETICS; GLIOMA; HEADACHE; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INBORN ERROR OF METABOLISM; INCIDENCE; LEUKOCYTOSIS; LINEAR SCLERODERMA; LIVER FUNCTION TEST; LIVER TOXICITY; LYME DISEASE; MARINESCO SJOGREN SYNDROME; MENINGISM; METACHROMATIC LEUKODYSTROPHY; MIGRAINE; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PELIZAEUS MERZBACHER DISEASE; PREVALENCE; PROTEIN CEREBROSPINAL FLUID LEVEL; RELAPSE; RISK; RISK FACTOR; SARCOIDOSIS; SEIZURE; STROKE; SYPHILIS; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT; VARICELLA ZOSTER VIRUS; VASCULITIS; VERTIGO; VIRUS ENCEPHALITIS; VOMITING; WHITE MATTER;

EID: 78650728243     PISSN: 10802371     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.CON.0000389941.99907.c8     Document Type: Article

References (42)

1. Duquette P, Murray TJ, Pleines J, et al. Multiple sclerosis in childhood: Clinical profile in 125 patients. J Pediatr 1987;111(3):359-363.
2. Ghezzi A, Deplano V, Faroni J, et al. Multiple sclerosis in childhood: Clinical features of 149 patients. Mult Scler 1997;3(1):43-46.
3. Banwell B, Kennedy J, Sadovnick D, et al. Incidence of acquired demyelination of CNS in Canadian children. Neurology 2009;72(3):232-239.
4. Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: A longitudinal study. Lancet Neurol 2006;5(11):932-936.
5. Krupp LB, Banwell B, Tenembaum S; International Pediatric MS Study Group. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2008;68(16 suppl 2):S7-S12.
6. Chabas D, Castillo-Trivino T, Mowry EM, et al. Vanishing MS T2-bright lesions before puberty: A distinct MRI phenotype? Neurology 2008;71(14):1090- 1093.
7. Dale RC, Branson JA. Acute disseminated encephalomyelitis or multiple sclerosis: Can the initial presentation help in establishing a correct diagnosis? Arch Dis Child 2005;90(6):636-639.
8. Alper G, Heyman R, Wang L. Multiple sclerosis and acute disseminated encephalomyelitis diagnosed in children after long-term follow-up: Comparison of presenting features. Dev Med Child Neurol 2009;51(6):480-486.
9. Banwell B, Krupp L, Kennedy J, et al. Clinical features and viral serologies in children with multiple sclerosis: A multinational observational study. Lancet Neurol 2007;6(9):773-781.
10. Alotaibi S, Kennedy J, Tellier R, et al. Epstein-Barr virus in pediatric multiple sclerosis. JAMA 2004;291(15):1875-1879.
11. Mikaeloff Y, Caridade G, Suissa S, Tardieu M. Clinically observed chickenpox and the risk of childhood-onset multiple sclerosis. Am J Epidemiol 2009;169(10):1260-1266.
12. Mikaeloff Y, Caridade G, Rossier M, et al.Hepatitis B vaccine and the risk of childhood-onset multiple sclerosis. Arch Pediatr Adolesc Med 2007;161(12):1176-1182.
13. Mikaeloff Y, Caridade G, Assi S, et al. Hepatitis B vaccine and risk of relapse after a first childhood episode of CNS inflammatory demyelination. Brain 2007; 130(pt 4):1105-1110.
14. Mikaeloff Y, Caridade G, Tardieu M, Suissa S. Parental smoking at home and the risk of childhood-onset multiple sclerosis in children. Brain 2007;130(pt 10):2589-2595.
15. Hanwell H, Vieth R, Bar-Or A, et al. Serum 25-hydroxyvitamin D status as a determinant of multiple sclerosis outcome following an initial demyelinating event in children. Mult Scler 2008;14:S6.
16. Oksenberg JR, Barcellos LF, Cree BA, et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet 2004;74(1):160-167.
17. Boiko AN, Gusev EI, Sudomoina MA, et al. Association and linkage of juvenile MS with HLA-DR2(15) in Russians. Neurology 2002;58(4):658-660.
18. Boster AL, Endress CF, Hreha SA, et al. Pediatric-onset multiple sclerosis in African-American black and European-origin white patients. Pediatr Neurol 2009;40(1):31-33.
19. Kennedy J, O'Connor P, Sadovnick AD, et al. Age at onset of multiple sclerosis may be influenced by place of residence during childhood rather than ancestry. Neuroepidemiology 2006;26(3):162-167.
20. Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 2009;66(1):54-59.
21. Ghezzi A. Clinical characteristics of multiple sclerosis with early onset. Neurol Sci 2004;25(suppl 4):S336-S339.
22. Waubant E, Chabas D, Okuda DT, et al. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs. adults. Arch Neurol 2009;66(8):967-971.
23. Simone IL, Carrara D, Tortorella C, et al. Course and prognosis in early-onset MS. Neurology 2002;59(12):1922-1928.
24. Wilejto M, Shroff M, Buncic JR, et al. The clinical features, MRI findings, and outcome of optic neuritis in children. Neurology 2006;67(2):258-262.
25. Boiko A, Vorobeychik G, Paty D, et al. Early onset multiple sclerosis: A longitudinal study. Neurology 2002;59(7):1006-1010.
26. Sindern E, Haas J, Stark E, Wurster U. Early onset MS under the age of 16: Clinical and paraclinical features. Acta Neurol Scand 1992;86(3):280-284.
27. Mikaeloff Y, Caridade G, Assi S, et al. Prognostic factors for early severity in a childhood multiple sclerosis cohort. Pediatrics 2006;118(3):1133-1139.
28. Mowry EM, Krupp LB, Milazzo M, et al. Vitamin D status is associated with relapse rate in pediatric-onset MS. Ann Neurol 2010;67(5):618-624.
29. Renoux C, Vukusic S, Mikaeloff Y, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med 2007;356(25):2603-2613.
30. Cohen JA, Antel JP. Does interferon beta help in secondary progressive MS? Neurology 2004;63(10):1768-1769.
31. Julian LJ, Im-Wang S, Chabas D, et al. Learning and memory in pediatric-onset multiple sclerosis. Mult Scler 2008;14:S258.
32. Kurne A, Oguz KK, Oz Aksu A, et al. Magnetic resonance imaging at first episode in pediatric multiple sclerosis retrospective evaluation according to KIDMUS and lesion dissemination in space criteria. Brain Dev 2010;32(6):487-494.
33. Mikaeloff Y, Suissa S, Vallee L, et al. First episode of acute CNS inflammatory demyelination in childhood: Prognostic factors for multiple sclerosis and disability. J Pediatr 2004;144(2):246-252.
34. Pohl D, Rostasy K, Reiber H, Hanefeld F. CSF characteristics in early-onset multiple sclerosis. Neurology 2004;63(10):1966-1967.
35. Chabas D, Ness J, Belman A, et al. Younger children with pediatric MS have a distinct CSF inflammatory profile at disease onset. Neurology 2010;74(5):399-405.
36. Mikaeloff Y, Caridade G, Tardieu M, Suissa S. Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: A comparative cohort study. Eur J Paediatr Neurol 2008;12(3):205-209.
37. Pohl D, Rostasy K, Gartner J, Hanefeld F. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology 2005;8(5):778-779.
38. Ghezzi A, Amato MP, Capobianco M, et al. Disease-modifying therapy in childhood-juvenile multiple sclerosis: Results of an Italian co-operative study. Mult Scler 2005;11(4):420-424.
39. Banwell B, Reder AT, Krupp L, et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology 2006;66(4):472-476.
40. Tenembaum SN, Segura MJ. Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology 2006;67(3):511-513.
41. Waubant E, Hieptas J, Stewart T, et al. Interferon beta-1a in children with multiple sclerosis is well tolerated. Neuropediatrics 2001;32(4):211-213.
42. Yeh EA, Ness J, Chabas D, et al. Breakthrough disease in pediatric MS patients: A pediatric network experience. Neurology 2009;72(11 suppl 3):A428.